← back to search

Valter Torri

Mario Negri Institute for Pharmacological Research · IT
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, and HER2/EGFR in Cancer Research.
h-index
91
citations
40,633
works
663
NIH funding
primary concept
Medicine
email

Recent publications

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.
2026cited by 1position: contributordoi
Supplementary Figure S13 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S9 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S11 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S4 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S2 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S6 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S9 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S4 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S7 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S8 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S1 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S3 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Data from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S1 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S1 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S7 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S2 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S2 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S1 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S8 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S2 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S11 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S12 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S14 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S15 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S14 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S3 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Figure S6 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi
Supplementary Table S6 from The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
2026cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 7 papers (2019–2025)Marina Chiara Garassino · Comprehensive Cardiovascular6 papers (2019–2025) · 4 papers (2023–2025)Giuseppe Viscardi · University of Campania "Luigi Vanvitelli"4 papers (2023–2025)Luca Porcu · Cancer Research UK Cambridge Center4 papers (2012–2024)Roberto Ferrara · University of Iowa4 papers (2019–2025)Alberto Zambelli · Ospedale Papa Giovanni XXIII3 papers (2012–2023) · 3 papers (2023–2025) · 3 papers (2023–2025)Marina Elena Cazzaniga · Azienda Socio Sanitaria Territoriale Lariana3 papers (2016–2019)Eliana Rulli · Mario Negri Institute for Pharmacological Research3 papers (2013–2021)Alberto Servetto · Southwestern Medical Center3 papers (2023–2025) · 2 papers (2023–2025)Corrado Magnani · University of Padua2 papers (2012–2016)Biagio Ricciuti · Harvard University2 papers (2025–2025)Carmine Pinto · University of Salerno2 papers (2012–2016) · 2 papers (2023–2025) · 2 papers (2023–2025)Jacobi Hines · Northwestern University2 papers (2023–2024)Giulia Veronesi · Vita-Salute San Raffaele University2 papers (2023–2024)